Quick Answer
Inmune Bio, Inc. reported Diluted EPS of $1.86 per share (loss) for fiscal year 2025.
Inmune Bio, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.86 | +11.8% |
| 2024 | -$2.11 | -26.3% |
| 2023 | -$1.67 | -9.9% |
| 2022 | -$1.52 | +19.1% |
| 2021 | -$1.88 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.24 | +60.0% | +77.1% |
| June 30, 2025 | -$1.05 | -110.0% | -144.2% |
| March 31, 2025 | -$0.43 | +29.5% | +28.3% |
| September 30, 2024 | -$0.60 | -25.0% | -20.0% |
| June 30, 2024 | -$0.50 | -38.9% | +18.0% |
| March 31, 2024 | -$0.61 | -69.4% | -27.1% |
| September 30, 2023 | -$0.48 | -11.6% | -33.3% |
| June 30, 2023 | -$0.36 | +5.3% | +0.0% |
- Inmune Bio, Inc. showed an increase of +11.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Inmune Bio, Inc.’s diluted eps has grown by 1.1% (from $1.88 per share (loss) to $1.86 per share (loss)).
- The most recent figure is from Inmune Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: